Bone Loss After Denosumab: Only Partial Protection with Zoledronate

Area of Science:

• Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Postmenopausal osteoporosis is a significant health concern.
• Long-term denosumab treatment effectively increases bone mineral density (BMD).
• Transitioning from denosumab to other osteoporosis therapies requires careful consideration.

Purpose of the Study:

• To evaluate the efficacy of a single zoledronate infusion in preserving BMD gains achieved with continuous denosumab therapy.
• To assess bone turnover markers after switching from denosumab to zoledronate.

Main Methods:

• A case series of six women with postmenopausal osteoporosis was analyzed.
• Patients received continuous denosumab for 7 years, followed by a single 5 mg zoledronate infusion.
• Bone mineral density (BMD) and serum PINP levels were measured before and after zoledronate treatment.

Main Results:

• Denosumab treatment significantly increased spine and total hip BMD.
• Following zoledronate, significant BMD declines were observed at both sites.
• Spine BMD remained above baseline, but hip BMD returned to baseline levels.
• Elevated serum PINP levels indicated inadequate bone turnover inhibition by zoledronate.

Conclusions:

• A single zoledronate infusion is insufficient to maintain BMD gains from long-term denosumab therapy.
• This regimen may not adequately suppress bone turnover in postmenopausal osteoporosis patients.
• Alternative strategies may be needed for effective BMD preservation after denosumab discontinuation.